The Africa IVD market is expected to grow at a CAGR of 2.8% from 2023 to 2030 to reach $1.49 billion by 2030.
After a comprehensive secondary and primary research study and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.
The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.
Based on product category, in 2023, the reagents & kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays & kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.
Based on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to its advantages such as high sensitivity and accuracy, high throughput capability, and the rising prevalence of infectious diseases.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.
Based on diagnostic approach, in 2023, the lab testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.
Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.
Based on geography, in 2023, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.
The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
After a comprehensive secondary and primary research study and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.
The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.
Based on product category, in 2023, the reagents & kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays & kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.
Based on technology, in 2023, the molecular diagnostics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to its advantages such as high sensitivity and accuracy, high throughput capability, and the rising prevalence of infectious diseases.
Based on application, in 2023, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.
Based on diagnostic approach, in 2023, the lab testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.
Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.
Based on geography, in 2023, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.
The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
Scope of the Report
Africa IVD Market Assessment-by Product Category
- Reagents & Kits
- Instruments
- Software & Services
Africa IVD Market Assessment-by Technology
- Molecular Diagnostics
- Point-of-care Diagnostics
- Immunoassay/Immunochemistry
- Biochemistry/Clinical Chemistry
- Whole Blood Glucose Monitoring
- Hematology
- Microbiology
- Coagulation & Hemostasis
- Other IVD Technologies
Africa IVD Market Assessment-by Application
- Infectious Diseases
- Oncology
- Diabetes
- Cardiology
- Nephrology
- Autoimmune Disorders
- Other Applications
Africa IVD Market Assessment-by Diagnostic Approach
- Lab Testing
- Point-of-care Testing
- OTC/Self-testing
Africa IVD Market Assessment-by End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Home Care
- Other End Users
Africa IVD Market Assessment-by Country
- South Africa
- Egypt
- Algeria
- Nigeria
- Morocco
- Kenya
- Tunisia
- Tanzania
- Rest of Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Dynamics
5. Africa IVD Market Assessment-by Product Category
6. Africa IVD Market Assessment-by Technology
7. Africa IVD Market Assessment-by Application
8. Africa IVD Market Assessment-by Diagnostic Approach
9. Africa In Vitro Diagnostics Market Assessment - by End User
10. Africa IVD Market Assessment-by Geography
11. Competitive Analysis
12. Company Profiles (Company Overview, SWOT Analysis for the Top 5 Companies, Financial Overview, Product Portfolio, and Strategic Developments)
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Becton Dickinson and Company
- bioMérieux SA
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Illumina Inc.
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd .
